Ascletis Pharma, Inc.

Ascletis Pharma, Inc.

0.50
EUR
0.00
(0.00%)
1.25BMarket Cap
Mar 30Next Earn

Total Valuation

EUR

As of June 30, 2026, Ascletis Pharma, Inc. carries a market capitalization of 1.25B, placing it among publicly traded companies globally. Its enterprise value stands at 960.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.25B
Enterprise Value960.38M

Important Dates

Ascletis Pharma, Inc.'s next confirmed earnings release is scheduled for March 30, 2027.

Earnings Date3/30/2027

Share Statistics

As of June 30, 2026, Ascletis Pharma, Inc. has 1.06B shares outstanding.

Shares Outstanding1.06B

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio4.27
P/TBV Ratio4.29

Financial Position

As of June 30, 2026, Ascletis Pharma, Inc. maintains a current ratio of 12.92, meaning it holds 12.9x the short-term assets needed to cover near-term liabilities.

Current Ratio12.92
Quick Ratio12.76
Debt / Equity0.16

Financial Efficiency

These figures cover the twelve months ended June 30, 2026.

Employee Count202.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, Ascletis Pharma, Inc.'s stock has declined approximately 66.67% over the past 52 weeks. The 50-day moving average sits at 0.77, while the 200-day moving average is 1.28.

52-Week Price Change-66.67%
50-Day Moving Average0.77
200-Day Moving Average1.28

Balance Sheet

EUR

As of June 30, 2026, Ascletis Pharma, Inc. holds 292.52M in cash and equivalents against 481,991.69 in total debt, resulting in a net debt position of -76.55M. Total book value stands at 292.98M, with working capital of 273.13M providing operational flexibility.

Cash & Cash Equivalents292.52M
Total Debt481,991.69
Net Debt-76.55M
Equity (Book Value)292.98M
Book Value Per Share0.28
Working Capital273.13M